AbbVie's Humira Dominates Despite Cheaper Rivals
• AbbVie has retained 96% of the U.S. Humira market share despite biosimilar competition • Humira brought in $21B in 2021 sales for AbbVie, making it the world's bestselling drug for the 10th straight year • U.S. healthcare system could save up to $6B if all Humira patients switched to biosimilars • Pharmacy benefits managers would lose 84% profits with a full Humira switch due to rebate schemes • PBM formulary tactics make it difficult for biosimilars to gain traction despite much lower pricing